remov epacadostat
model lower pt
epacadostat fail show benefit melanoma
monotherapi result disappoint
continu see substanti valu base busi one
deepest pipelin smid-cap biotech remov
epacadostat model pt
one anticip data readout smid-cap biotech year
fail show epacadostat benefit monotherapi
melanoma announc disappoint top-line result phase
trial show epacadostat combin merck keytruda
patient unresect metastat melanoma show benefit
primari endpoint progression-fre surviv overal surviv
os second primari endpoint expect reach statist signific
final analysi report hazard ratio hr ci
os ci suggest benefit placebo
base result recommend extern data
monitor committe edmc studi stop repres
bear case scenario trial saw share trade
rang see note compani pursu extens
biomark analys tmb ido express determin subgroup activ
could potenti inform trial design on-going futur phase
studi epacadostat tumor type includ nsclc rcc head
neck bladder cancer analys expect complet
next sever month present medic congress
remov valu epacadostat model pt melanoma
gener view key prove ground immunotherapi phase
data gener date epacadostat combin appear
promis tumor type previous model per share
risk-adjust npv epacadostat assign probabl success rang
depend tumor type may continu
ascrib risk-adjust valu epacadostat opportun beyond melanoma
 unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
assum minim pipelin valu contribut epacadostat pend
addit clinic data suggest viabl path forward
remov epacadostat valu model reduc
revenu estim respect leav
expens estim unchang though anticip updat guidanc
provid earn call earli may remind current
sg guidanc non-gaap includ
prelaunch cost associ epacadostat would expect cost
unlik realiz success epacadostat tumor type
would view upsid current valuat
jakafi iclusig olumi base busi continu support one deepest
pipelin smid-cap biotech remain ow previous note see note
believ share head data alreadi reflect
signific amount investor skeptic readout believ share
like trade rang howev also believ
investor sidelin ahead binari data like
step broader stori includ one deepest
pipelin smid-cap biotech support jakafi base busi
myelofibrosi iclusig royalti europ royalti baricitinib approv
olumi europ fda decis forecast non-gaap revenu
base busi see growth
franchis suffici sustain drug discoveri develop
platform pipelin program reflect current valuat includ
risk-adjust npv jak inhibit jakafi/itacitinib gvhd
risk-adjust npv b-cell malign
earli clinic pre-clin asset drug discoveri engin
also see potenti addit upsid emerg target clinic asset
explicitli reflect valuat
cholangiocarcinoma/bladd cancer capmatinib c-met inhibitor partner
novarti nsclc brd inhibitor pim
inhibitor variou advanc malign phase asset
inhibitor aml/sclc also deep
pipelin i/o program address variou target arg gitr
axl/mer though given failur epacadostat remain cautiou
program pend compel control clinic data
upcom key catalyst includ baricitinib fda adcomm april
pivot data expect next key catalyst share
april fda advisori committe meet adcomm baricitinib
rheumatoid arthriti baricitinib partner cover morgan
stanley analyst david rising believ mani investor discount valu
baricitinib follow complet respons letter receiv
april anticip volatil around panel like begin
releas fda brief materi april provid first detail
look potenti issu agenc drug includ agenc
view thromboembol dvt/pe risk baricitinib preview
panel larg pharma team beyond baricitinib
panel expect investor focu top-line result pivot
trial jakafi steroid refractori acut gvhd expect
snda like incyt view key expans opportun
jakafi light increas incid gvhd signific mortal
patient also expect updat financi guidanc
outlook compani earn call earli may
jak backbon lucr partnership fuel oncolog platform ow
lucr partnership fuel oncolog platform ow
deriv pt risk-adjust sum-of-the-part sop analysi
forecast expect revenue/profit drug/condit
combin assum wacc termin growth
deriv npv assign probabl factor
drug/condit reflect clinic regulatori risks/tim sum
risk-adjust npv add cash excess requir invest
commerci out-performance jakafi base case earlier
anticip us approv baricitinib ra provid increment upsid
addit clinic data epacadostat show potenti util tumor
increas penetr myelofibrosi polycythemia vera continu
drive jakafi revenu peak sale fuel industry-
lead engin baricitinib us approv ra result peak
royalti
jakafi underperform appear unlik reach compani
peak guidanc baricitinib approv delay need sizabl
outcom studi assum minim valu pipelin beyond jakafi
iclusig olumi royalti
jakafi provid stabl revenu backbon
revenu grow annual
patent expiri driven continu uptak
myelofibrosi polycythemia vera
driven potenti commerci execut
clinic asset drug discoveri platform
uniqu mid-cap biotech sector
possess deep pipelin
earli clinic pre-clin asset
addit commerci revenu royalti
key valuat driver commerci
execut approv drug well
perceiv clinic regulatori risk
data pivot trial
jakafi gvhd
detail data epacadostat echo-
trial
risk achiev price
jakafi uptak less anticip
baricitinib fail obtain approv and/or
clinic failur emerg oncolog
pt includ jakafi sale myelofibrosi mf polycythemia vera pv
royalti jakavi sale europ iclusig sale all/cml europ royalti
baricitinib sale rheumatoid arthriti atop dermat jak use graft-versus-
host diseas gvhd usag b-cell malign includ
risk-adjust npv robust earli clinic pre-clin asset
well drug discoveri engin
exhibit risk-adjust valu molecul
valuat methodolog use risk-adjust sum-of-the-part methodolog valu
examin clinic regulatori commerci risk opportun
individu indic region assign probabl success account
likelihood achiev revenues/expens
discount rate use discount rate line compani
termin growth rate model forecast revenu expens
opportun beyond anticip exclus period product
product ip beyond expiri assign termin valu
illion except per-shar data
otal jakafi evenu
otal aricitinib oyalti
product evenu
total evenu
total evenu
provis incom axe
